Theralase Technologies Inc. V.TLT

Forbes on BTD published in Nature.

[Dumbeldorfwhite]

for all those hanging their hat on BTD being some lifesaver.

https://www.forbes.com/sites/frankdavid/2019/02/23/btd-event-study/

[Kayz88]

I don't think it's a lifesaver, but it'll be an amazing stop gap for all the low raises. I can't access the other article but I'm curious what the market cap was of the companies before and after BTD. Reason being, TLT is sub 100 million CAD in market cap, IIRC, IBRX shot up to multiple billions after their BTD? Before dropping down. So IF the other non-gainers move into the 1

[Alamir1111]

https://search.app?link=https%3A%2F%2Fwww.biv.com%2Fnews%2Ftechnology%2Ffda-approves-cancer-drug-developed-by-bcs-zymeworks-9847508@utm_campaign=aga@utm_source=agsadl2%2Csh%2Fx%2Fgs%2Fm2%2F4

[Alamir1111]

Sorry page not avialable 

[CancerSlayer]

A BTD is one piece (big or small) of value creation for an "investor"...this is not a speculative play for me & most on this board. Although technically this company may be considered a pure play (clinically), our preclinical data certainly extends well beyond the boundaries of NMIBC, unlike many other smaller biotechs. There are many examples in the past 5+ years of true pure plays

[reconsider]

Just look at IBRX. They received BTD in December '19. $1.5 to $7 in 1 month (x4.5). $13 in July '20 (x8.5). $30 in Feb '21 (x15). Had a lot to do with COVID stonking also, but never the less. I can't see how an unknown microcap company at $50M wouldn't have a solid value raise if their wonder particle get's BTDed. That would put us in the radar of every single analyst